Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Drug Use Statement, 22742-22743 [2024-06955]
Download as PDF
khammond on DSKJM1Z7X2PROD with NOTICES
22742
Federal Register / Vol. 89, No. 64 / Tuesday, April 2, 2024 / Notices
to cease and desist orders. (19 U.S.C.
1337(f)(1)).
The Commission is soliciting
submissions on public interest issues
raised by the recommended relief
should the Commission find a violation,
specifically: a general exclusion order
directed to certain blood flow restriction
devices with rotatable windlasses and
components thereof that infringe claims
1, 4, 15, and 16 of U.S. Patent No.
7,842,067 (‘‘the ’067 patent’’) that are
imported, sold for importation, and/or
sold after importation; a limited
exclusion order directed to certain
blood flow restriction devices with
rotatable windlasses and components
thereof that infringe claims 1, 4, 15, and
16 of the ’067 patent, infringe U.S.
Trademark Registration Nos. 3,863,064
and 5,046,378, and/or infringe the
asserted Trade Dress and that are
imported, sold for importation, and/or
sold after importation by Respondents
Anping Longji Medical Equipment
Factory; Dongguanwin Si Hai Precision
Mold Co., Ltd.; Eiffel Medical Supplies
Co., Ltd.; Empire State Distributors Inc.;
EMRN Medical Equipment; GD Tianwu
New Material Tech Co., Ltd.; Hengshui
Runde Medical Instruments Co., Ltd.;
Putian Dima Trading Co., Ltd.; Rhino
Inc.; Shanghai Sixu International
Freight Agent Co., Ltd.; Shenzhen
Anben E-Commerce Co., Ltd.; Shenzhen
TMI Medical Supplies Co., Ltd.;
Shenzhen Yujie Commercial and
Trading Co., Ltd.; Wuxi Emsrun
Technology Co., Ltd.; Wuxi Golden
Hour Medical Technology Co., Ltd.; and
Wuxi Puneda Technology Co., Ltd.
(collectively, ‘‘Defaulting
Respondents’’); and cease and desist
orders directed to each Defaulting
Respondent. Parties are to file public
interest submissions pursuant to 19 CFR
210.50(a)(4).
The Commission is interested in
further development of the record on
the public interest in this investigation.
Accordingly, members of the public and
interested government agencies are
invited to file submissions of no more
than five (5) pages, inclusive of
attachments, concerning the public
interest in light of the ALJ’s
Recommended Determination on
Remedy and Bond issued in this
investigation on March 19, 2024.
Comments should address whether
issuance of the recommended remedial
orders in this investigation would affect
the public health and welfare in the
United States, competitive conditions in
the United States economy, the
production of like or directly
competitive articles in the United
States, or United States consumers.
VerDate Sep<11>2014
17:06 Apr 01, 2024
Jkt 262001
In particular, the Commission is
interested in comments that:
(i) explain how the articles potentially
subject to the recommended remedial
orders are used in the United States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the recommended orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or thirdparty suppliers have the capacity to
replace the volume of articles
potentially subject to the recommended
orders within a commercially
reasonable time; and
(v) explain how the recommended
orders would impact consumers in the
United States.
Written submissions must be filed no
later than by close of business on April
26, 2024.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above. The Commission’s paper
filing requirements in 19 CFR 210.4(f)
are currently waived. 85 FR 15798 (Mar.
19, 2020). Submissions should refer to
the investigation number (‘‘Inv. No.
337–TA–1364’’) in a prominent place on
the cover page and/or the first page. (See
Handbook for Electronic Filing
Procedures, https://www.usitc.gov/
secretary/fed_reg_notices/rules/
handbook_on_electronic_filing.pdf).
Persons with questions regarding filing
should contact the Secretary (202–205–
2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment by marking each document
with a header indicating that the
document contains confidential
information. This marking will be
deemed to satisfy the request procedure
set forth in Rules 201.6(b) and
210.5(e)(2) (19 CFR 201.6(b) &
210.5(e)(2)). Documents for which
confidential treatment by the
Commission is properly sought will be
treated accordingly. Any non-party
wishing to submit comments containing
confidential information must serve
those comments on the parties to the
investigation pursuant to the applicable
Administrative Protective Order. A
redacted non-confidential version of the
document must also be filed
simultaneously with any confidential
filing and must be served in accordance
with Commission Rule 210.4(f)(7)(ii)(A)
(19 CFR 210.4(f)(7)(ii)(A)). All
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
information, including confidential
business information and documents for
which confidential treatment is properly
sought, submitted to the Commission for
purposes of this investigation may be
disclosed to and used: (i) by the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel, solely for cybersecurity
purposes. All contract personnel will
sign appropriate nondisclosure
agreements. All nonconfidential written
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: March 25, 2024.
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2024–06897 Filed 4–1–24; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
[OMB Number 1117–0043]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Previously Approved Collection; Drug
Use Statement
Drug Enforcement
Administration, Department of Justice.
ACTION: 30-Day notice.
AGENCY:
The Drug Enforcement
Administration, Department of Justice
(DOJ), will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection was previously
published in the Federal Register on
December 24, 2024 allowing a 60-day
comment period.
DATES: Comments are encouraged and
will be accepted for 30 days until June
3, 2024.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
SUMMARY:
E:\FR\FM\02APN1.SGM
02APN1
Federal Register / Vol. 89, No. 64 / Tuesday, April 2, 2024 / Notices
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Kannessia Jordan, Section Chief, Office
of Compliance, Policy Administration
Section, 700 Army Navy Drive,
Arlington, VA 22202, telephone: 571–
776–2262, email: Kannessia.S.Jordan@
DEA.gov.
Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
khammond on DSKJM1Z7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Written comments and
recommendations for this information
collection should be submitted within
30 days of the publication of this notice
on the following website
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
30-day Review—Open for Public
Comments’’ or by using the search
function and entering either the title of
the information collection or the OMB
Control Number 1117–0043. This
information collection request may be
viewed at www.reginfo.gov. Follow the
instructions to view Department of
Justice, information collections
currently under review by OMB.
DOJ seeks PRA authorization for this
information collection for three (3)
years. OMB authorization for an ICR
cannot be for more than three (3) years
without renewal. The DOJ notes that
information collection requirements
submitted to the OMB for existing ICRs
VerDate Sep<11>2014
17:06 Apr 01, 2024
Jkt 262001
receive a month-to-month extension
while they undergo review.
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
Overview of This Information
Collection
[Notice: 024–025]
1. Type of Information Collection:
Extension of a previously approved
collection.
2. The Title of the Form/Collection:
Drug Questionnaire.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
Form number: DEA–341 (Common
Form). The sponsoring component is the
Drug Enforcement Administration.
4. Affected public who will be asked
or required to respond, as well as the
obligation to respond: Affected Public:
Individuals or households. Abstract:
This collection requires the drug history
of any individual seeking employment
with DEA. DEA policy states that a past
history of illegal drug use may result in
ineligibility for employment. The form
asks job applicants specific questions
about their personal history, if any, of
illegal drug use.
5. The obligation to respond is
voluntary but applications will not be
reviewed without the completion of the
form.
6. An estimate of the total number of
respondents: The total or estimated
number of respondents for the Drug
Questionnaire is 4,727.
7. The amount of time estimated for
an average respondent to respond: The
time per response is seven minutes.
8. Frequency: 1 per application or
selection.
9. An estimate of the total annual
burden (in hours) associated with the
collection: The total annual burden
hours for this collection is 551 hours.
10. An estimate of the total annual
cost burden associated with the
collection, if applicable: $0.
If additional information is required
contact: Darwin Arceo, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 4W–218,
Washington, DC.
Dated: March 25, 2024.
Darwin Arceo,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2024–06955 Filed 4–1–24; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
22743
Aerospace Safety Advisory Panel;
Meeting.
National Aeronautics and
Space Administration (NASA).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, as
amended, the National Aeronautics and
Space Administration announces a
forthcoming meeting of the Aerospace
Safety Advisory Panel (ASAP). The
ASAP will hold its Second Quarterly
Meeting for 2024. This discussion is
pursuant to carrying out its statutory
duties for which the Panel reviews,
identifies, evaluates, and advises on
those program activities, systems,
procedures, and management activities
that can contribute to program risk.
Priority is given to those programs that
involve the safety of human flight.
DATES: Wednesday, April 17, 2024, 3
p.m. to 4:30 p.m., central time.
ADDRESSES: Public attendance will be
virtual only. See dial-in information
below under SUPPLEMENTARY
INFORMATION.
SUMMARY:
Ms.
Lisa M. Hackley, ASAP Administrative
Officer, NASA Headquarters,
Washington, DC 20546, (202) 358–1947
or lisa.m.hackley@nasa.gov.
SUPPLEMENTARY INFORMATION: As noted
above, this meeting is only available
telephonically. Any interested person
must use a touch-tone phone to
participate in this meeting. Any
interested person may call the USA toll
free conference call number 888–566–
6133; passcode 8343253 and then the #
sign. At the beginning of the meeting,
members of the public may make a
verbal presentation to the Panel limited
to the subject of safety in NASA, not to
exceed 5 minutes in length. To do so,
members of the public must contact Ms.
Lisa M. Hackley at lisa.m.hackley@
nasa.gov or at (202) 358–1947 at least 48
hours in advance. Any member of the
public is permitted to file a written
statement with the Panel via electronic
submission to Ms. Hackley at the email
address previously noted. Written
statements should be limited to the
subject of safety in NASA.
The agenda for the meeting includes
the following topics:
—Updates on the International Space
Station Program
—Updates on the Commercial Crew
Program
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\02APN1.SGM
02APN1
Agencies
[Federal Register Volume 89, Number 64 (Tuesday, April 2, 2024)]
[Notices]
[Pages 22742-22743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06955]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
[OMB Number 1117-0043]
Agency Information Collection Activities; Proposed eCollection
eComments Requested; Extension of a Previously Approved Collection;
Drug Use Statement
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: 30-Day notice.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration, Department of Justice
(DOJ), will be submitting the following information collection request
to the Office of Management and Budget (OMB) for review and approval in
accordance with the Paperwork Reduction Act of 1995. The proposed
information collection was previously published in the Federal Register
on December 24, 2024 allowing a 60-day comment period.
DATES: Comments are encouraged and will be accepted for 30 days until
June 3, 2024.
FOR FURTHER INFORMATION CONTACT: If you have additional comments
especially on the estimated public
[[Page 22743]]
burden or associated response time, suggestions, or need a copy of the
proposed information collection instrument with instructions or
additional information, please contact Kannessia Jordan, Section Chief,
Office of Compliance, Policy Administration Section, 700 Army Navy
Drive, Arlington, VA 22202, telephone: 571-776-2262, email:
[email protected].
SUPPLEMENTARY INFORMATION: Written comments and suggestions from the
public and affected agencies concerning the proposed collection of
information are encouraged. Your comments should address one or more of
the following four points:
--Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the Bureau of Justice
Statistics, including whether the information will have practical
utility;
--Evaluate the accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used;
--Evaluate whether and if so how the quality, utility, and clarity of
the information to be collected can be enhanced; and
--Minimize the burden of the collection of information on those who are
to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses.
Written comments and recommendations for this information
collection should be submitted within 30 days of the publication of
this notice on the following website www.reginfo.gov/public/do/PRAMain.
Find this particular information collection by selecting ``Currently
under 30-day Review--Open for Public Comments'' or by using the search
function and entering either the title of the information collection or
the OMB Control Number 1117-0043. This information collection request
may be viewed at www.reginfo.gov. Follow the instructions to view
Department of Justice, information collections currently under review
by OMB.
DOJ seeks PRA authorization for this information collection for
three (3) years. OMB authorization for an ICR cannot be for more than
three (3) years without renewal. The DOJ notes that information
collection requirements submitted to the OMB for existing ICRs receive
a month-to-month extension while they undergo review.
Overview of This Information Collection
1. Type of Information Collection: Extension of a previously
approved collection.
2. The Title of the Form/Collection: Drug Questionnaire.
3. The agency form number, if any, and the applicable component of
the Department sponsoring the collection: Form number: DEA-341 (Common
Form). The sponsoring component is the Drug Enforcement Administration.
4. Affected public who will be asked or required to respond, as
well as the obligation to respond: Affected Public: Individuals or
households. Abstract: This collection requires the drug history of any
individual seeking employment with DEA. DEA policy states that a past
history of illegal drug use may result in ineligibility for employment.
The form asks job applicants specific questions about their personal
history, if any, of illegal drug use.
5. The obligation to respond is voluntary but applications will not
be reviewed without the completion of the form.
6. An estimate of the total number of respondents: The total or
estimated number of respondents for the Drug Questionnaire is 4,727.
7. The amount of time estimated for an average respondent to
respond: The time per response is seven minutes.
8. Frequency: 1 per application or selection.
9. An estimate of the total annual burden (in hours) associated
with the collection: The total annual burden hours for this collection
is 551 hours.
10. An estimate of the total annual cost burden associated with the
collection, if applicable: $0.
If additional information is required contact: Darwin Arceo,
Department Clearance Officer, United States Department of Justice,
Justice Management Division, Policy and Planning Staff, Two
Constitution Square, 145 N Street NE, 4W-218, Washington, DC.
Dated: March 25, 2024.
Darwin Arceo,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2024-06955 Filed 4-1-24; 8:45 am]
BILLING CODE 4410-09-P